From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement

The denominator in early phase CAR T-cell trials examining novel taret antigens

Last Updated: Friday, August 18, 2023

This commentary by Muhammad Bilal Abid discusses the need for patient-centric endpoints in early-phase clinical trials examining lymphoid malignancies, and these trials should be more inclusive of patients with high-risk disease and more transparent in toxicity reporting.  

Lancet
Advertisement
News & Literature Highlights
Advertisement
Advertisement